Tekmira and OnCore Tie the Knot, Plan to Focus on HBV Treatment
In November 2014, Dicerna Pharmaceuticals licensed the technology for delivery of DCR-PH1, its investigational drug for the rare liver disorder primary hyperoxaluria type 1. The deal is expected to generate up to $24.5 million, plus royalties, for Tekmira.
Genetic Engineering & Biotechnology News - Mon, 12 Jan 2015 07:11

Alnylam to Webcast Presentation at 33rd Annual JP Morgan Healthcare ...
... for the treatment of AAT deficiency-associated liver disease; ALN-TMP targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-GO1 targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 ...
MarketWatch - Mon, 05 Jan 2015 13:01

Alnylam Launches “Alnylam 2020″ Guidance for Advancement and ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its “Alnylam 2020″ guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines.
Finances.com - Thu, 08 Jan 2015 04:56

Allena Pharmaceuticals to Present at 2015 JP Morgan Healthcare Conference
Allena's lead program, ALLN-177, is in an ongoing Phase 2 clinical trial in patients with hyperoxaluria. The company's proven approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where ...
Rock Hill Herald (press release) - Thu, 08 Jan 2015 05:41

Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN ...
... for the treatment of AAT deficiency-associated liver disease; ALN-TMP targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-GO1 targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria type 1 ...
MarketWatch - Mon, 05 Jan 2015 05:03

Poster Highlights Rapid and Durable Effect of DCR-PH1 in Mouse Model of PH1
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster session at the ...
Business Wire (press release) - Tue, 14 Oct 2014 14:22

Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at ...
MarketWatch - Tue, 14 Oct 2014 05:07

Researchers Demonstrate Promise of Dicerna Investigational Therapy in ...
... Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company's therapeutic candidate for the treatment of primary hyperoxaluria ...
Business Wire (press release) - Mon, 30 Jun 2014 05:00

Why Dicerna Pharmaceuticals Inc Stock Skyrocketed
Motley Fool - Mon, 30 Jun 2014 14:01

The Latest Discovery by Dicerna Pharmaceuticals (NASDAQ:DRNA)
Stocks.org - Tue, 01 Jul 2014 20:44

Dicerna Pharmaceuticals Flying After Positive Pre-Clinical Data On PH1
Bidness Etc - Mon, 30 Jun 2014 12:07

Allena Pharmaceuticals Secures $25 Million Series B Financing
“The positive response and level of interest we have received from investors is a great reflection of our seasoned management team, the market opportunity and the unmet need that ALLN-177 meets in the treatment of hyperoxaluria,” said Alexey Margolin, ...
Business Wire (press release) - Thu, 04 Dec 2014 04:00

Biotech partners at Allena fund a march toward PhIII with $25M venture round
FierceBiotech - Thu, 04 Dec 2014 05:53


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014